logo
Plus   Neg
Share
Email

Regeneron Pharma Stops Placebo Group Enrollment For REGEN-COV On Advice From IDMC

Regeneron Pharmaceuticals, Inc. (REGN) Thursday said it stopped enrollment into the placebo group for its Phase 3 trial of REGEN-COV in non-hospitalised patients with COVID-19 as per the recommendations from the Independent Data Monitoring Committee or IDMC.

According to the company, the IDMC found clinical efficacy in reducing the rate of hospitalization and death with both the 1,200 mg and 2,400 mg doses of REGEN-COV compared to placebo.

Regeneron will continue to enroll patients into both the 1,200 mg and 2,400 mg REGEN-COV treatment groups.

The trial was participated by more than 8,000-patients.

The company noted that the preclinical data showed that REGEN-COV effectively neutralizes emerging strains of the virus, which are becoming increasingly common.

George Yancopoulos, president, and chief scientific officer at Regeneron said, "Our cocktail approach using two functionally-independent antibodies safeguards against variants that may impact potency to a single antibody."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Johnson & Johnson's (JNJ) Covid-19 vaccine is expected to be back on track as early as this weekend as a decision is expected after the advisory panel meeting of the U.S. Centers for Disease Control and Prevention (CDC) slated on April 23, according to Dr. Anthony Fauci, the chief medical adviser to President Joe Biden. MK-4482, the experimental antiviral drug for COVID-19, showed promise to prevent and treat SARS-CoV-2 infection in hamster study, according to the scientists of National Institutes of Health or NIH. The drug significantly decreased levels of virus and disease damage in the lungs of hamsters treated for SARS-CoV-2 infection. MK-4482, delivered orally, is now in Phase 2 and 3 human clinical studies. Beverages giant Coca-Cola reported a 19 percent decline in profit for the second quarter from last year as a revenue growth of 5 percent and improved margins were offset by higher income taxes and interest expense. However, adjusted earnings per share and revenues topped analysts' expectations. The company also maintained its adjusted earnings and organic revenue growth outlook for fiscal 2021.
Follow RTT